Navigation Links
Researcher targets gene regulators on link between arsenic, cancer

EAST LANSING, Mich. To determine how arsenic increases the risk of lung cancer and to identify potential treatments, a Michigan State University researcher will use $1.7 million in federal funding during the next five years to examine why certain genes disrupt cells, leading to the disease.

Chengfeng Yang, a physiology assistant professor with the College of Veterinary Medicine and MSU's Center for Integrative Toxicology, will be studying the role of very small ribonucleic acids called microRNAs. These microRNAs regulate genes, which control how a cell behaves.

The research project, which will study those processes in cultured human cells and mice, is funded by the National Institutes of Health.

"Arsenic is one of the most common environmental pollutants, and long-term arsenic exposure through drinking water is associated with increased risk of lung cancers specifically and some other cancers as well," Yang said. "The long-term goal of this study is to determine the mechanism by which this happens and to identify targets for the treatment and prevention of cancers resulting from arsenic exposure."

Since the levels of microRNAs are different when comparing normal tissue cells to cancer cells, Yang and his team are trying to determine if that difference is because of the tumor or if it is what caused the tumor in the first place.

"Does microRNA play a role in tumor development? Can carcinogens such as arsenic cause the deregulation of microRNA that leads to cancer development? That's what we need to find out," Yang said.

To accomplish that, Yang will look at two specific microRNAs miRNA200b and miRNA200c and the role they play in converting normal human bronchial epithelial cells to tumor cells when exposed to arsenic. Those specific microRNAs were chosen because during screening, they were the only two that were different when comparing normal cells with cells transformed by cells.

"A single microRNA has the ability to regulate more than 100 gene functions, playing an important role in cell behavior and whether cells function normally or potentially change to a cancerous cell," Yang said. "More than one-third of all human genes are believed to be regulated by microRNAs, and when microRNA levels are too high or too low, they disrupt the normal function of cells and lead to disease."

Uncovering how microRNAs react to carcinogens and lead to tumor development could help researchers discover biomarkers and identify people who may be more prone to develop tumors.

"With this information, we could potentially diagnose and treat people much sooner," Yang said.

As part of his project, Yang also will investigate the role of two genes called ZEB1 and ZEB2 in this process, because the appearance of these two genes can cause the depletion of miRNA-200b and miRNA-200c. He will further examine the role of these two genes in arsenic-induced tumors by studying mice with the ZEB1 and ZEB2 genes removed.


Contact: Jason Cody
Michigan State University

Related medicine news :

1. Researchers study relationship of oral cancers and periodontal disease
2. HIV care providers and researchers applaud release of national HIV/AIDS strategy
3. Researchers envision better disease surveillance to improve public health
4. U-M researchers identify gene mutation that causes rare form of deafness
5. MIT researchers find that Sirtuin1 may boost memory and learning ability
6. OU researcher developing novel therapy for Alzheimers disease
7. Researchers identify factors behind blood-making stem cells
8. Parkinsons Transplant Mystery Solved, Researchers Say
9. BIDMC researcher receives Young Investigator Award from Prostate Cancer Foundation
10. Researchers suggest new paradigm for breast cancer screening
11. Of lice and man: Researchers sequence human body louse genome
Post Your Comments:
Related Image:
Researcher targets gene regulators on link between arsenic, cancer
(Date:6/25/2016)... Viejo, California (PRWEB) , ... June 25, 2016 , ... ... to fit their specific project," said Christina Austin - CEO of Pixel Film Studios. ... fully customizable and all within Final Cut Pro X . Simply select a ...
(Date:6/25/2016)... ... June 25, 2016 , ... ... recover from injury. Recently, he has implemented orthobiologic procedures as a method for ... is one of the first doctors to perform the treatment. Orthobiologics are substances ...
(Date:6/24/2016)... CA (PRWEB) , ... June 24, 2016 , ... A ... procedures that most people are unfamiliar with. The article goes on to state that ... but also many of these less common operations such as calf and cheek reduction. ...
(Date:6/24/2016)... ... June 24, 2016 , ... Marcy was in a crisis. Her son James, eight, was out ... family verbally and physically. , “When something upset him, he couldn’t control his emotions,” remembers ... would throw rocks at my other children and say he was going to kill them. ...
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. Amanda Cheng, an ... Cheng has extensive experience with all areas of orthodontics, including robotic Suresmile technology, ... , Micro-osteoperforation is a revolutionary adjunct to orthodontic treatment. It can be ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... June 23, 2016 Research and Markets ... Issue 52" report to their offering. ... treatment creates a favourable commercial environment for MedImmune to enter. ... base that will serve to drive considerable growth for effective ... serve to cap sales considerably, but development is still in ...
(Date:6/23/2016)... 2016 , , , WHEN: ... 2016 , , , , LOCATION: , , , Online, ... , , EXPERT PANELISTS:  , , , Frost & Sullivan,s Global ... Bird; Senior Industry Analyst, Divyaa Ravishankar and Unmesh Lal, Program Manager ... pharmaceutical industry is witnessing an exceptional era. Several new demand spaces, ...
(Date:6/23/2016)... the establishment of Astellas Farma Colombia (AFC), a new affiliate with operations headquartered in Bogota. Colombia ... ... Sandra ... ... Astellas is a pharmaceutical company ...
Breaking Medicine Technology: